Literature DB >> 9768783

Increased plasma concentration of adrenomedullin in patients with subarachnoid hemorrhage.

K Kikumoto1, A Kubo, Y Hayashi, N Minamino, S Inoue, K Dohi, K Kitamura, K Kangawa, H Matsuo, H Furuya.   

Abstract

UNLABELLED: Adrenomedullin (AM) is a potent hypotensive peptide originally identified in pheochromocytoma tissues. Impaired cardiovascular conditions, such as hypertension, myocardial infarction, and septic shock, stimulate production of AM. This study was performed to determine whether subarachnoid hemorrhage (SAH) altered plasma AM concentration. Plasma concentrations of AM in 17 patients with SAH were measured for 2 wk after the onset of SAH by AM-specific radioimmunoassay. Plasma concentrations of AM were increased in patients with SAH throughout the study period, compared with those in control subjects. Plasma concentrations of AM in patients classified as Hunt and Kosnik grade III or IV were significantly higher than those classified as Hunt and Kosnik grade I or II on the day of and the day after the onset of SAH. However, plasma concentrations of AM were unaffected by angiographic vasospasm. These findings suggest that plasma concentrations of AM are increased in patients with SAH and may reflect the severity of SAH. IMPLICATIONS: Adrenomedullin has been reported to affect the cerebral circulation. This study was performed to determine whether subarachnoid hemorrhage, a typical cerebrovascular disorder, altered plasma adrenomedullin concentrations. We found that plasma adrenomedullin concentrations increased in patients with subarachnoid hemorrhage, although no relationship was found between plasma adrenomedullin concentration and angiographic vasospasm. Plasma adrenomedullin concentration may reflect the severity of hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768783     DOI: 10.1097/00000539-199810000-00021

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats.

Authors:  Juntao Yang; Rongqian Wu; Mian Zhou; Ping Wang
Journal:  Peptides       Date:  2010-02-02       Impact factor: 3.750

2.  A preliminary study of metalloproteins in CSF by CapLC-ICPMS and NanoLC-CHIP/ITMS.

Authors:  Jenny Ellis; Estela Del Castillo; Maria Montes Bayon; Rudolf Grimm; Joseph F Clark; Gail Pyne-Geithman; Steve Wilbur; Joseph A Caruso
Journal:  J Proteome Res       Date:  2008-07-29       Impact factor: 4.466

3.  Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion.

Authors:  Juntao Yang; Rongqian Wu; Xiaoling Qiang; Mian Zhou; Weifeng Dong; Youxin Ji; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

4.  Human vasoactive hormone adrenomedullin and its binding protein rescue experimental animals from shock.

Authors:  Rongqian Wu; Weifeng Dong; Xiaoling Qiang; Youxin Ji; Tianpen Cui; Juntao Yang; Mian Zhou; Steven Blau; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Peptides       Date:  2008-03-08       Impact factor: 3.750

Review 5.  Hyponatremia in the Neurologically Ill Patient: A Review.

Authors:  David P Lerner; Starane A Shepherd; Ayush Batra
Journal:  Neurohospitalist       Date:  2020-01-10

6.  Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study.

Authors:  Teruhide Koyama; Nagato Kuriyama; Yosuke Suzuki; Satoshi Saito; Ryota Tanaka; Motoshi Iwao; Megumu Tanaka; Takakuni Maki; Hiroki Itoh; Masafumi Ihara; Takayuki Shindo; Ritei Uehara
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

7.  Adrenomedullin Is a Diagnostic and Prognostic Biomarker for Acute Intracerebral Hemorrhage.

Authors:  Francisco J Julián-Villaverde; Laura Ochoa-Callejero; Eva Siles; Esther Martínez-Lara; Alfredo Martínez
Journal:  Curr Issues Mol Biol       Date:  2021-06-11       Impact factor: 2.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.